Mortgage Blog
UPMC Vision Institute opens Urgent Eye Care Clinic
New facility — the first of its kind in Pennsylvania — will treat “acute ophthalmology emergencies.”
Dallas leads in U.S. exit valuations as VC activity begins to rebound, according to Deloitte
Activity appears to be rebounding after exit values plummeted to $12 billion last year following a peak of $20 billion in 2021, according to a Deloitte report.
Cologuard maker Exact Sciences plans huge expansion in Arizona
A molecular diagnostic company that focuses on the early detection and prevention of colorectal cancer is expanding into other cancer tests as it plans a major expansion and tons of hiring in Phoenix.
Health Care of the Future Innovation Awards: Regence BlueCross BlueShield
Regence set out to address two common pain points in health care: prior authorization by health plans for medical services and siloing patient data.
Exclusive: Major hospital system makes multiple CEO moves
The executive leadership moves come as the San Antonio health system continues to spread its footprint.
Health Care of the Future Innovation Awards: Carta Healthcare
Matt Hollingsworth founded Carta Healthcare in 2017 to help health care providers better manage patient medical data.
Greater Baltimore banks slow pace of branch closures in 2023. Here’s who cut the most.
Baltimore's largest banks had different strategies when it came to managing their bank branch networks over the past 15 months. Here's who closed — and opened — the most locations.
Truist trims board size as former CEO Kelly King, HPU’s Nido Qubein, others to depart at end of year
Eight members will leave Truist Financial's board of directors in a significant shift for the bank, which has faced criticism for a board size that has been significantly larger than its financial-sector peers.
Raleigh biotech launched with $60M. A year later, it’s shutdown
A Raleigh company has folded less than a year after launching with tens of millions in financial backing and a goal to turn psychedelics into a treatment for depression.
Raleigh biotech launched with $60M. A year later, it’s shut down
A Raleigh company has folded less than a year after launching with tens of millions in financial backing and a goal to turn psychedelics into a treatment for depression.